Precigen Inc
Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of … Read more
Precigen Inc (PGEN) - Total Liabilities
Latest total liabilities as of September 2025: $129.40 Million USD
Based on the latest financial reports, Precigen Inc (PGEN) has total liabilities worth $129.40 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Precigen Inc - Total Liabilities Trend (2011–2024)
This chart illustrates how Precigen Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Precigen Inc Competitors by Total Liabilities
The table below lists competitors of Precigen Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jupiter Fund Management Plc
PINK:JFHHF
|
USA | $366.80 Million |
|
MANDARIN ORIENTAL DL-05
F:1C4
|
Germany | €918.90 Million |
|
General Interface Solution GIS Holding Ltd
TW:6456
|
Taiwan | NT$31.79 Billion |
|
CHTC Helon Co Ltd
SHE:000677
|
China | CN¥978.68 Million |
|
Bank Sinarmas Tbk
JK:BSIM
|
Indonesia | Rp40.60 Trillion |
|
Shanghai Baosteel Packaging
SHG:601968
|
China | CN¥4.93 Billion |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
China | CN¥130.20 Million |
|
Petroreconcavo S.A
SA:RECV3
|
Brazil | R$3.33 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Precigen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.76 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Precigen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Precigen Inc (2011–2024)
The table below shows the annual total liabilities of Precigen Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $106.75 Million | +228.02% |
| 2023-12-31 | $32.55 Million | -63.73% |
| 2022-12-31 | $89.72 Million | -64.47% |
| 2021-12-31 | $252.51 Million | +2.06% |
| 2020-12-31 | $247.41 Million | -35.58% |
| 2019-12-31 | $384.05 Million | +13.81% |
| 2018-12-31 | $337.45 Million | +12.37% |
| 2017-12-31 | $300.31 Million | -20.93% |
| 2016-12-31 | $379.82 Million | +37.04% |
| 2015-12-31 | $277.16 Million | +65.98% |
| 2014-12-31 | $166.98 Million | +89.48% |
| 2013-12-31 | $88.13 Million | -81.38% |
| 2012-12-31 | $473.20 Million | +40.80% |
| 2011-12-31 | $336.09 Million | -- |